Cogent Biosciences, Inc. financial data

Symbol
COGT on Nasdaq
Location
275 Wyman Street, 3 Rd Floor, Waltham, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 528 % -37.8%
Debt-to-equity 40.7 % +136%
Return On Equity -126 % -78.2%
Return On Assets -89.7 % -48.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 142M shares +28.9%
Common Stock, Shares, Outstanding 140M shares +26.6%
Entity Public Float 869M USD -10.2%
Common Stock, Value, Issued 141K USD +28.2%
Weighted Average Number of Shares Outstanding, Basic 138M shares +24.9%
Weighted Average Number of Shares Outstanding, Diluted 138M shares +24.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 256M USD +16.8%
General and Administrative Expense 51.3M USD +24.9%
Costs and Expenses 308M USD +18.1%
Operating Income (Loss) -308M USD -18.1%
Nonoperating Income (Expense) 13.2M USD -27%
Net Income (Loss) Attributable to Parent -294M USD -21.5%
Earnings Per Share, Basic -2 USD/shares -28.1%
Earnings Per Share, Diluted -2 USD/shares -28.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 125M USD +29.1%
Assets, Current 397M USD +16.3%
Property, Plant and Equipment, Net 5.27M USD -24.8%
Operating Lease, Right-of-Use Asset 18.6M USD -9.67%
Other Assets, Noncurrent 4.49M USD -7.69%
Assets 426M USD +10.9%
Accounts Payable, Current 16M USD +6.43%
Employee-related Liabilities, Current 10.5M USD +35.9%
Liabilities, Current 62.2M USD +17.3%
Operating Lease, Liability, Noncurrent 14.6M USD -10.5%
Other Liabilities, Noncurrent 2.37M USD
Liabilities 123M USD +78%
Accumulated Other Comprehensive Income (Loss), Net of Tax 208K USD -76.8%
Retained Earnings (Accumulated Deficit) -1.09B USD -37.2%
Stockholders' Equity Attributable to Parent 302M USD -3.88%
Liabilities and Equity 426M USD +10.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -66.5M USD -26.6%
Net Cash Provided by (Used in) Financing Activities 25M USD -88.3%
Net Cash Provided by (Used in) Investing Activities 69.4M USD +6545%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 140M shares +26.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 27.8M USD -82.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 126M USD +29.5%
Deferred Tax Assets, Valuation Allowance 219M USD +39.1%
Operating Lease, Liability 17.5M USD -7.35%
Payments to Acquire Property, Plant, and Equipment 547K USD +681%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -295M USD -22.3%
Lessee, Operating Lease, Liability, to be Paid 25.2M USD -9.92%
Property, Plant and Equipment, Gross 12.6M USD +4.77%
Operating Lease, Liability, Current 1.71M USD +12.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.7M USD -5.07%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.84M USD +2.19%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 7.77M USD -15.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.13M USD -20.9%
Deferred Tax Assets, Operating Loss Carryforwards 64.3M USD +34.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.18M USD +2.21%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 40.3M USD +4.38%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%